PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.75%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.33%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
1.77%
Gross profit growth of 1.77% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
4.04%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 2.49%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
15.41%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.80%. Joel Greenblatt would see if unique processes drive exceptional profitability.
13.61%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
13.59%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.91%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
13.59%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.91%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
0.02%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.15%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.02%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.19%. Joel Greenblatt would see a meaningful advantage if shares are undervalued.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative OCF growth while Medical - Pharmaceuticals median is 9.42%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-100.00%
Negative FCF growth while Medical - Pharmaceuticals median is 11.21%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
160.73%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 38.59%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
56.92%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 18.65%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
34.46%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 11.84%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
138.65%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 31.20% over a decade. Joel Greenblatt might see a standout compounder of earnings.
37.21%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 18.42%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-32.24%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
331.44%
Equity/share CAGR of 331.44% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
86.25%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.01%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
35.83%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.84%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
166.67%
5Y dividend/share CAGR of 166.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Receivables growth far exceeding Medical - Pharmaceuticals median. Jim Chanos suspects potential red flags in revenue quality.
-3.29%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-1.36%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
1.52%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-6.02%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-0.62%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.